Loading...
XTSX
KNE
Market cap4mUSD
Dec 05, Last price  
0.04CAD
1D
16.67%
1Q
-12.50%
Jan 2017
-76.67%
IPO
-98.29%
Name

Kane Biotech Inc

Chart & Performance

D1W1MN
XTSX:KNE chart
P/E
P/S
2.80
EPS
Div Yield, %
Shrs. gr., 5y
10.22%
Rev. gr., 5y
4.21%
Revenues
2m
+1,296.75%
024,09817,15600000159,94541,899104,624244,7561,035,302506,2731,693,5241,341,5741,607,7752,668,352148,9802,080,879
Net income
-3m
L-39.92%
-1,009,650-955,759-1,089,955-1,076,844-877,247-973,254-1,221,149-1,459,495-1,447,365-1,614,908-1,709,997-2,548,748-2,786,174-3,260,999-960,178-3,716,686-4,604,566-3,889,892-5,034,103-3,024,507
CFO
-4m
L+27.62%
-808,870-843,129-798,377-1,073,400-764,261-792,058-940,305-1,155,293-1,166,443-1,049,161-1,388,494-2,363,319-2,044,247-2,853,997-955,372-3,938,970-2,289,190-3,043,472-3,221,626-4,111,346

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
IPO date
May 07, 2003
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT